Monday 16 Jun, 2025 10:38 PM
Site map | Locate Us | Login
   Nucleus Software appoints Aabhinna Khare as CMO to lead global brand transformation    Rategain Travel Technologies Ltd leads losers in 'A' group    Karma Energy Ltd leads losers in 'B' group    Zydus Life subsidiary ZHL appoints Swati Dalal as MD    GRM Overseas jumps 26% in eight days    Volumes jump at Anand Rathi Wealth Ltd counter    Algoquant Fintech incorporates WOS, Algoquant Global Securities    Desco Infratech slides after CFO Prinkle Sanjay Jain resigns    Punjab & Sind Bank drops for fifth straight session    Central Bank of India eases for fifth straight session    Indian Overseas Bank drops for fifth straight session    UCO Bank drops for fifth straight session    Bank of India down for fifth straight session    Tips Music Ltd down for fifth straight session    Tata Consumer Products Ltd drops for fifth straight session 
Saravan Stocks
       
Company News
Aster DM Healthcare Ltd
Stock Alert: Dixon Tech, Torrent Pharma, United Spirits, Aster DM Healthcare, J Kumar Infraprojects
May 21,2025   Hrs IST

Securities in F&O Ban:

RBL Bank and Manappuram Finance shares are banned from F&O Trading on 21 May 2025.

Upcoming Results:

IndusInd Bank, Oil & Natural Gas Corporation (ONGC), Astral, Colgate Palmolive (India), H.G. Infra Engineering, InterGlobe Aviation, Ircon International, Mankind Pharma, National Aluminium Co, NTPC Green Energy, Oil India, Power Finance Corp, Rail Vikas Nigam, Trident, VRL Logistics will declare their results later today.

Stocks to Watch:

Dixon Technologies (India)’s consolidated net profit surged 321.2% to Rs 400.82 crore on 121% jump in revenue from operations to Rs 10,292.54 crore in Q4 FY25 over Q4 FY24.

Torrent Pharmaceuticals reported 10.9% jump in consolidated net profit to Rs 498 crore on 7.9% increase in revenue from operations to Rs 2,909 crore in Q4 FY25 over Q4 FY24.

United Spirits’ consolidated net profit jumped 74.7% to Rs 421 crore on 8.9% increase in net sales (excluding excise duty) to Rs 3,031 crore in Q4 March 2025 over Q4 March 2024.

Gland Pharma’s consolidated net profit declined 3.1% to Rs 186.54 crore in Q4 FY25, compared with Rs 192.42 crore in Q4 FY24. Revenue from operations fell 7.3% YoY to Rs 1,424.91 crore in Q4 FY25.

Aster DM Healthcare reported consolidated net profit of Rs 79.02 crore in Q4 FY25 compared with net loss of Rs 24.03 crore in Q4 FY24.Revenue from operations increased 2.7% YoY to Rs 1,000.34 crore during the quarter ended 31st March 2025.

J kumar Infraprojects’ consolidated net profit rose 12.1% to Rs 114.20 crore on 14.6% jump in revenue from operations to Rs 1,632.74 crore in Q4 FY25 over Q4 FY24.

Senores Pharmaceuticals (SPL)‘s US subsidiary, Senores Pharmaceuticals US has entered into an agreement to acquire US FDA- approved ANDA for Enalapril Maleate Tablets from Wockhardt. Enalapril is used for treatment of hypertension, heart failure.

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 41994449
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL Securities Private Limited